• About us
• Contact

Advertisement

Organisation › Details

Pharmalink AB

Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. With a successful history in pharmaceutical sales and marketing, and highly experienced, dynamic management team, Pharmalink is currently focused on the development of valuable, de-risked projects using a repurposing and reformulation strategy. It has two late-stage clinical phase products under development, Nefecon® and Busulipo™, having successfully divested its Xepol® product in 2010. Pharmalink is actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications. *

 

	Start	2012-01-04 existent
	End	2017-11-15 renamed
	Group	Calliditas Therapeutics (Group)
	Today	Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
	Successor	Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
	Industry	pharmaceutical
	Industry 2	Nefecon®
	Person	Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
	Person 2	Johansson, Fredrik (Pharmalink AB 201708– CFO before Birdstep Technology/Techstep ASA)
	Region	Stockholm
	Country	Sweden
	Street	26B Wallingatan
	City	11124 Stockholm
	Tel	+46-8-411-3005
		Address record changed: 2021-10-26
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Calliditas Therapeutics (Group)

• [1] Calliditas Therapeutics AB. (8/25/20). "Press Release: Calliditas Appoints Group General Counsel"....
• [2] Calliditas Therapeutics AB. (7/24/20). "Press Release: Calliditas Reorganizes Its Management Team"....
• [3] Calliditas Therapeutics AB. (7/2/20). "Press Release: Exercise of Over-allotment Option and End of the Stabilization Period"....
• [4] Calliditas Therapeutics AB. (6/5/20). "Press Release: Calliditas Therapeutics Prices Its Initial Public Offering on The Nasdaq Global Select Market in the United States"....
• [5] Calliditas Therapeutics AB. (5/14/20). "Press Release: Calliditas Publicly Files Registration Statement with SEC for a Proposed Initial Public Offering in the United States"....
• [6] Calliditas Therapeutics AB. (4/5/19). "Press Release: Elmar Schnee and Diane Parks Proposed as New Board Members of Calliditas Therapeutics". Stockholm....
• [7] Calliditas Therapeutics AB. (1/8/19). "Press Release: Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America"....
• [8] Genkyotex S.A.. (8/20/18). "Press Release: Genkyotex Secures an up to €7.5 Million Gross Financing to further Expand the Development of Its Lead Product". Archamps....
• [9] Calliditas Therapeutics AB. (11/20/17). "Press Release: Surrogate Marker and Design of Calliditas Therapeutics’ IgA Nephropathy Phase 3 Study Agreed with the FDA". Stockholm....
• [10] Genkyotex S.A.. (7/27/17). "Press Release: Genkyotex Provides Business Update for Q2 2017". Archamps....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.